Andrew Leuchter is a Psychiatry physician. ClinicalTrials.gov lists 7 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
760 Westwood Plz Ste 37-452
Los Angeles, CA 900245055
Telephone
310-825-0207Provider last certified this registry record 17 Jul 2024.
Clinical trials
- Network-targeted Theta-burst Stimulation for Episodic Memory Improvement in Mild Cognitive Impairment
Sponsor: University of California, Los Angeles
- Adaptive Design Study of NEST sTMS in Subjects With Major Depressive Disorder
Sponsor: Wave Neuroscience
- Synchronized Transcranial Magnetic Stimulation (sTMS) in Major Depressive Disorder
Sponsor: Wave Neuroscience
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Abbott LaboratoriesProgram year20252 payments
- Abbott LaboratoriesProgram year20242 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
100%Mood Stabilizer30.5%Lamotrigine100%Part D<11 patientsGabapentinoids28.8%Gabapentin100%Part D<11 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
10 NIH research awards on record, funded 1986–2026 per NIH RePORTER. The latest:
- Resonant Frequency rTMS: A Novel Approach to Target Circuit Modulation in MDD
University of California Los Angeles
FY2026$762,933R01MH135293 - Resonant Frequency rTMS: A Novel Approach to Target Circuit Modulation in MDD
University of California Los Angeles
FY2025$642,796R01MH135293 - Resonant Frequency rTMS: A Novel Approach to Target Circuit Modulation in MDD
University of California Los Angeles
FY2024$738,063R01MH135293
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Philip Scheltens
Inserm
Rafael Tabarés‐Seisdedos
Universitat de València
Nick C. Fox
UK Dementia Research Institute
Perminder S. Sachdev
Department of Health and Aged Care
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”